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ABSTRACT

Accumulating research has demonstrated that polyphenolic compounds from
natural products, such as pomegranate, may have antioxidant and neuroprotective
properties in animal models of Alzheimer’s disease (AD). However, the present study
explores whether the administration of a pomegranate peel extract could have a
rescuing effect on AD pathology in aged transgenic animal models of AD. These mice
already have abundant AD pathology since amyloid beta (Aβ) deposition continues
with time. Two doses of the extract or a control solution were fed daily to groups of
transgenic mice (R1.40), ranging in age from 24-30 months. Treatment and behavioral
assessment lasted thirty-seven days total. Mice were tested in the Morris water maze
and the Y-maze for improvements in spatial, long-term and working memory
functions. This was followed by the measurements of cortical amyloid precursor
protein (APP) and Aβ levels along with other relevant biomarkers for AD. The
resulting data demonstrated a lack of change in cognitive performance in the mazes, as
well as the precursor protein and other enzymes associated with the amyloidogenic
pathway. However, biochemical analyses revealed an alteration in the levels and ratio
of the Aβ peptides that favored a diminution in AD pathogenesis. This was featured by
the lowering of the more amyloidogenic Aβ1-42 peptide and an increase in the Aβ1-40
peptide. Further experiments revealed that this reversal could be the product of the
modification of the gamma-secretase enzyme responsible for generating the more
amyloidogenic form.

In conclusion, pomegranate peel extract appears to contain

ingredients that act as gamma-secretase modulators, which may be identified and
developed as compounds for use in future drug therapy.
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CHAPTER 1

INTRODUCTION

Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that
slowly impairs daily functioning through loss of memory and cognition. It is the most
common cause of dementia, affecting 13% of people over the age of 65 (Hebert 2003).
As populations of the United States and other countries begin to age, AD becomes a
more common cause of death (Xie 2008). However, the effects that the disease has on
daily living is not the only major concern. According to the latest data released by the
Alzheimer’s Association, the total spending for Alzheimer’s care and other dementias
was over $200 billion in 2012 and it is expected to increase five-fold by 2050 (Thies
2013). In addition to increasing awareness and action among the public health
community, it is imperative that an effective disease modifying treatment, or perhaps
even a cure, is developed in the near future to combat this debilitating disease.
Most cases of AD show up in people aged 60 or above. This form of the
disease is called late-onset Alzheimer’s disease (LOAD). Although the causes for
LOAD are still poorly understood, several studies have loosly linked it to a version of
the apolipoprotein E (APOE) gene called APOE ε4. The presence of this gene can
increase a person’s risk for developing LOAD (Corder 1993). AD can also have
earlier origins in people, and these cases are called early-onset Alzheimer’s disease
(EOAD). Albeit rare, it occurs in individuals between the ages of 30 and 40. A
majority of these early-onset cases are called Familial Alzheimer’s disease (FAD),
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where a genetic predisposition is the contributing cause. The main three genes
commonly associated with FAD are: amyloid precursor protein (APP), presenilin-1
(PS-1), and presenelin-2 (PS-2). They occur on chromosomes 21, 14, and 1,
respectively. A mutation in any of these three genes, or inheriting the mutated form,
causes FAD in people (Ertekin-Taner 2007). Mutation in the gene leads a change in
the structural arrangement of the coded protein, thus changing the way it it processed,
as in the case of APP, and how it affects downstream enzymatic activity, as in the case
of PS-1 and PS-2. The result of having one or more of these mutations is the increased
likelihood of developing the characteristic hallmarks found in Alzheimer’s disease.
These familial AD genes are guiding the way for animal-based models to effectively
study the disease and test novel therapies.
Pharmacological therapies that are currently being studied, including those
under clinical trials, are focusing on interrupting the underlying pathogenesis of AD in
the brain (Herrmann 2011). A common but general target is beta amyloid (Aβ)
plaques, one of the major hallmarks of the disease that is known to cause neuronal cell
death (Hardy 1992). However, there is still some uncertainty about which specific
byproducts of the disease should be targeted and what their roles are in the overall
pathogenesis of the disease. Pharmaceutical drugs that target a specific enzyme
involved in AD may lead to moderate to severe side effects (May et al 2011,
Svedruzic 2013). This may be due to the fact that that same enzyme also has nonpathological functions within the cell. Although there are still no proven ways to treat
or prevent disease progression, there recently has been accumulating evidence that diet
can affect risk (Solfrizzi 2011).
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Natural compounds found in certain fruits have been shown to possess
neuroprotective and antioxidant abilities when studied with in vivo and in vitro models
of AD (Choi 2012). In many transgenic mouse and rat studies, dietary intake of fruits
such as blueberry, bilberry, and black currant at an early age slowed Aβ deposition in
the brain and improved learning ability and overall cognition, as compared to controls
(Andres-Lacueva 2005, Pannangrong 2011, Vepsalainen 2013). It is believed that such
compounds, called polyphenols, can alleviate the oxidative stress that is caused by
reactive oxgen species, which are normally induced by Aβ (Ortiz, 2004). Under a
large nine-year clinical research study called the Kame project, dementia-free subjects
that consumed vegetable and fruit juices three or more times a week demonstrated a
decreased likelihood of being diagnosed with AD, compared to those who consumed
less (Dai 2006). The diagnoses were based mainly on the criteria for the National
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s
Disease and Related Disorders Association. Again, this study and others like it have
provided supporting evidence that such natural products are effective in preventing the
pathogenic events leading to AD. What is yet to be fully determined is the
effectiveness of these natural compounds at reversing amyloidgenic processing and
deposition in old age, and improving cognition in an already diseased brain. Such
studies are necessary to evaluate the potential of natural products as forms of
treatment, rather than just as preventative measures.
The hypothesis of this study is that a pomegranate peel extract, a fruit with
high levels of antioxidant polyphenols, can be used as a short-term treatment to help
alleviate the cognitive and biochemical features of AD in already aged transgenic
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animal models. In a 2004 study, researchers looked at the effects of a blueberry
supplemented diet on age-related deficits in rats. They found that polyphenolic
compounds from the fruit were able to cross the blood brain barrier and localize to
regions of the brain important for learning and memory (Andres-Lacueva 2005).
Similarly, this study will not only reveal the effectiveness of naturally occurring foods
as forms of treatment, but it will also help to better characterize the mechanism of the
effects of pomegranate extract. The results of this study may help the research
community realize the potential of alternative therapies towards alleviating the
symptoms of late stages of AD, and dementia in general.
This hypothesis will be tested by first choosing an AD transgenic animal
model that demonstrates the cognitive and behavioral decline that is seen in AD and
exhibits the biochemical hallmarks of the disease. After mice are bred, aged, and
genotyped, treatment and control groups will be determined. Administration of the
extract at different doses, or the control solution, will follow for a short period. During
treatment, animals will first be evaluated for their cognitive and learning abilities
through various behavioral tasks. This will be followed by post-mortem tissue
examination of regions of the brain that are known to be compromised during AD.
The tissues will be used to measure levels of key enzymes shown to play a role in Aβ
development or degradation. Brain tissues will also be tested for levels of APP, a
protein whose sequential proteolysis by two enzymes generates Aβ peptides. This will
reveal the efficacy of pomegranate at ameliorating the cognitive and biochemical
features of the disease.
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Pomegranate (Punica granatum L.) has been chosen as the fruit candidate for
this study for several reasons. First, pomegranate has a long history of being used as a
traditional remedy for a variety of illnesses. Only recently has this fruit been
researched and characterized using scientific methodology. Secondly, it has been
specifically shown to possess higher levels of antioxidant polyphenols, such as
punicalagin, ellagic acid, and gallic acid, and antioxidant potency in comparison to
other fruits and fruit juices (Kelawala 2004, Loren 2005, Seeram 2008). With regards
to its bioavailability in vivo, a study on punicalagin-fed rats found that only a small
fraction of this compound and its metabolites were found in feces and urine (Cerda
2003). This indicates its high absorption and bioavailability in animals. Studies have
also identified pomegranate’s antioxidant, anticarcinogenic, and anti-inflammatory
activities through its application towards preventing cancer, diabetes, cardiovascular
disease and dental conditions (Jurenka 2008). Extracts from the peel in particular have
been shown to have significantly higher levels of antioxidant activity in comparison to
the pulp and seed fractions (Li 2006). The peel also has high levels of antioxidant
activity in the brains of adult rats (Abdel Moneim 2012). In an attempt to harness
many of these properties of the pomegranate fruit, this study will use a crude extract
obtained from the peel of the fruit. A crude extract may be beneficial because it is
believed that the synergistic action of different compounds from a fruit is better than
that of any single purified compound (Jurenka 2008, Seeram et al 2005).
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CHAPTER 2

REVIEW OF LITERATURE

Thirty years ago, the scientific community knew very little about AD. Since then,
researchers have made significant advances, resulting in a better understanding of its
biochemical and clinical features. One of these advances is the development of
transgenic animal models that carry copies of the mutated genes found in familial AD.
With these genes, these models then develop the characteristic features of the disease,
both behavioral and biochemical, and can be more easily studied. New treatments can
also be tested on the animals to determine their global effects.
The two characteristic neuropathological hallmarks of AD are extracellular Aβ
plaques and intracellular tangles of the microtubule-stabilizing protein tau. It has been
widely established that the hyperphosphorylation of tau sequesters normal tau into
tangles of filaments, while the oligomerization of Aβ peptides, a cleavage product of
the transmembrane spanning APP, leads to the development of senile plaques (Alonso
2001). The plaque aggregates are mainly composed of Aβ peptides ranging from 3643 amino acids in length. These are generated after being sequentially cleaved from
the protein APP by the beta-site APP-cleaving enzyme 1 (BACE1), also known as βsecretase, followed by γ-secretase, a protein complex with presenilin-1 as its catalytic
site (Haass 2007). The non-amyloidogenic pathway in APP processing involves a
different enzyme called α-secretase, which cleaves between the β- and γ- cleavage
sites and thus precludes Aβ formation (Haass 1993).
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In AD, the Aβ1-40 and Aβ1-42 isoforms are the prime constituents of cerebral
plaques. Even though the Aβ1-40 species is ten times more prevalent than its
counterpart, the Aβ1-42 is more aggregation-prone and neurotoxic to cells (Walsh &
Selkoe 2007). This extracellular aggregation of amyloid-beta into plaques has been
shown to initiate the pathogenesis of AD, leading to extensive synaptic dysfunction,
neuronal loss, and dementia. This cascade of events is collectively known as the
amyloid hypothesis (Hardy 1992, Selkoe 1993). Recent studies also claim that the
soluble clusters of Aβ called oligomers, and the insoluble fractions, are the species
responsible for cell toxicity and death. The soluble fraction has also been better
correlated with disease severity in AD patients (Mc Donald 2010, McLean 1999).
Treatments for Alzheimer’s are at the moment limited in number and their overall
efficacy. Currently, there are four cholinesterase inhibitors and one N-methyl-Daspartate receptor antagonist that have been FDA approved for the treatment of AD.
These medications are not disease modifying and do not halt the progression of AD
(Ozudogru 2012). Efforts to develop effective treatment strategies have generally
focused on targeting Aβ production and aggregation, since it has been closely linked
to disease pathogenesis. This has been approached either by down-regulating APP
generation or its amyloidogenic processing, by directly inhibiting Aβ oligomerization,
or by promoting Aβ clearance enzymes such as neprilysin and insulin degrading
enzyme (IDE) to decrease plaque deposition (Querfurth 2010).
Secondary to this is the regulation of inflammation and oxidative stress, both
which are mediated by plaque deposition and lead to neuronal loss (Hardy 2002).
Although these treatment mechanisms have been observed with pharmaceutical drugs
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such as NSAIDs and statins, accumulating evidence has demonstrated that natural
products may exhibit similar activities in the brain (Shukla 2008, Weggen 2003,
Wilkinson 2012). One advantage, as already stated, is that these natural products have
exceptional safety profiles. Many of them have long been used as traditional remedies
for a number of ailments. A plethora of studies have already looked at the effects of
various natural remedies in different model systems of AD. Some of these products
have been shown to improve cognitive and behavioral symptoms when studied in vivo.
In addition, reductions in Aβ peptide formation and plaque deposition have been
observed. As potential treatments for AD, a notable feature that is shared among many
of these products is their abundance in bioactive polyphenolic antioxidants (Essa
2012). In addition to antioxidant activities, polyphenols have also displayed potent
anti-amyloidogenic activity (Ono 2004, Riviere 2008). However, not all diets have
therapeutic effects on AD.
There is accumulating evidence suggesting that certain diets can actually
increase the risk of developing AD. A diet that is high in fat and cholesterol has been
shown to accelerate Alzheimer’s pathology in APP transgenic mice (Refolo 2000).
Cholesterol-fed animals have even been used as models of AD (Sparks 2008). Trace
amounts of inorganic copper that is found in drinking water and supplements has also
been suggested to induce beta-amyloid plaque deposition (Sparks 2006). In addition, a
diet high in the amino acid methionine, such as red meat and eggs, has been linked to
elevated Aβ levels and behavioral impairments in an APP transgenic mouse model
(Zhuo 2010). However, even more important is the evidence in support of certain diets
to help reduce the risk of AD.
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The curry spice curcumin has been shown to suppress proinflammatory
cytokines, oxidative proteins, and plaque pathology in AD mouse models (Cole 2007,
Lim et al 2001). Similar effects have been found with pepper and cinnamon in other
AD models (Chonpathompikunlert 2010, Frydman-Marom 2011). In addition, walnuts
have been found to reduce age-related cognitive and motor deficits in vivo and
ameliorate Aβ-peptide induced cell death in PC12 cells (Muthaiyah 2011, Willis
2009). Even beverages such as green tea and coffee have displayed antioxidant effects
and increased cognitive performance in vivo (Essa 2012). In addition to these
products, a number of studies have revealed the beneficial effects of particular fruits
and berries on AD and age-related deficits.
From biochemistry to bioavailability, the pomegranate fruit itself has already
been extensively studied. There have already been a number of findings substantiating
its numerous health benefits for AD. In one experimental study, long-term
administration of pomegranate juice reduced hippocampal Aβ1-42 and extracellular
amyloid plaques in young APP transgenic mice. Cognitive performance and behavior
was also improved (Hartman 2006). In another study, punicalagin and ellagic acid, the
major polyphenols of pomegranate, were found to be BACE1 inhibitors found in the
peel of the fruit (Kwak 2005). Furthermore, ellagic acid itself was found to reduce
Aβ1-42 cytotoxicity toward SH-SY5Y neuroblastoma cells by preventing its
oligomerization (Feng 2009).
In addition to pomegranate, other fruits have also shown promising results. A
study on aged blueberry-fed rats found that anthocyanins from the fruit were able to
cross the blood brain barrier and localize in regions important for learning and
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memory (Andres-Lacueva 2005). In a separate study, aged rats that were given an 18
gm/kg extract of blueberry had enhanced performance in the Morris water maze
spacial navigation task (Joseph 1999). Additionally, researchers have found that a
blueberry extract exhibits equal neuroprotection against Aβ toxicity in both middle
and old-aged rats as well as APP/PS1 mice through a specific mechanism involving
protection against reactive oxygen species (ROS) (Brewer 2010).
Aside from blueberry, another study looked at the short term treatment of 20%
red grape juice on AD modeled rats. Memory performance was improved in the
passive avoidance task. In addition, free radicals were neutralized and oxidative stress
was reduced, both of which are cardinal features of AD (Siahmard 2012). An eightweek diet supplemented with 2% blackberry also improved cognitive and motor
performance to aged Fischer 344 rats. This was assessed by tasks that require balance
and coordination as well as short-term memory function. These effects were mainly
attributed to increased antioxidant and anti-inflammatory levels in the brain due to the
action of polyphenols (Shukitt-Hale 2009). These studies demonstrate that fruits and
other diets seem to be effective therapeutic options to decrease the risk of developing
AD and other age-related deficits. However, what is yet to be fully evaluated is the
effectiveness of such products in reversing AD pathogenesis in aged transgenic AD
models.
The aim of this study was to evaluate the potential of a short-term treatment of
pomegranate to reverse, not prevent, the cognitive deficits and aggregation of Aβ in
transgenic animal models as compared to vehicle control. This was accomplished by
utilizing reliable cognitive tasks and analyzing performance. This study was also used
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to help illustrate the specific mechanisms of pomegranate in the aging brain. By
looking at the changes in important biomarkers for AD, such as APP and Aβ, it was
possible to evaluate the activity of pomegranate.
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CHAPTER 3

METHODOLOGY

Pomegranate extract preparation
The pomegranate peel extract that was used in this study (POMELLA®;
http://www.pomextract.com/index.php) is a proprietary commercially available and
patented botanical extract obtained from Verdure Sciences (Noblesville, IN, USA). It
was standardized to polyphenol (61.5% gallic acid equivalents), punicalagins (29.5 %)
and ellagic acid (2.3%) content by the Bioactive Botanical Research Laboratory at the
University of Rhode Island (Principal Investigator: Dr. Navindra Seeram) according to
previously reported methods (Jean-Gilles 2013, Seeram 2005). The powdered extract
was dissolved in saline at two concentrations, 100 mg/kg and 200 mg/kg, by
vortexing. Pure saline was prepared as the control. The extract solutions were stored at
–20°C for the entire duration of the study.

Study population
The study was conducted on the B6.129-Tg(APPSw)40Btla/Mmjax transgenic
animal model, also known as R1.40. These transgenics were developed by Bruce T.
Lamb by inserting the entire 400-kb human APP gene containing the Swiss familial
AD (FAD) mutation using a yeast artificial chromosome (YAC) and a 250-kb flanking
sequence. The R1.40 model develops amyloid beta deposits in the hippocampus and
frontal cortex at 24 to 26 months of age (Lamb 1999). In addition, the total levels of
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the Aβ1-42 peptide are also 7 to 8-fold higher in the hemizygous groups, compared to
hemizygotes for the wild-type human gene (Lamb 1997). Hemizygous colonies were
ordered from Jackson Laboratory under an Institutional Animal Care and Use
Committee (IACUC) approved protocol to be used for this study.
Preliminary studies from the University of Rhode Island (URI) have already
established the learning and memory deficits associated with the R1.40 model
(Subaiea 2013). Spatial memory functions were assessed in the Morris water maze and
the Y-maze, both of which rely on the integrity of the cortex and hippocampal regions.
Aged female APP transgenic mice (n=19) and control wild-type mice (n=18) were
given daily trials for 8 days in the MWM, followed by probe trials. In the Y-maze, the
spontaneous alternation ratio was measured for each group. Baseline results showed a
significant impairment in long-term memory retention and working memory function
compared to wild type controls (Subaiea 2013). Therefore, these animals can be
deemed as useful models for the research of AD. During experimental preparations,
animals were housed in standard mouse cages at the URI animal quarter rooms with a
12:12 hour light-dark cycle. Temperature was maintained at 22°C. Food and water
was made available ad libitum. The protocols for this experiment were approved by
the URI IACUC. Animals were kept under supervision by a veterinarian throughout
the course of the entire study.

Transgenic animal experiments
Hemizygous YAC APP transgenic mice aged 24-30 months were given the
pomegranate extract or a control solution daily to determine its overall effectiveness in
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reversing AD. Mice were assigned to one of three groups in a fashion so as to equalize
the age variation within and between the groups. The three groups were assigned as
follows: 200 mg/kg/day extract in saline (n=8), 100 mg/kg/day extract in saline (n=8),
and vehicle control (n=7). Doses of even higher concentration have been deemed safe
to administer in vivo (Patel 2008). The animal numbers for each group were calculated
as the minimum needed based on standard power analysis, justified for scientific and
statistical purposes. The daily administration of the extract was done carefully through
oral gavage to ensure the precise delivery of the extract or control solution. Treatment
continued for three weeks. Previous studies on natural products and animal models of
AD have demonstrated significant effects after only a single month of administration
(Pannangrong 2011, Sehgal 2012). On day 15 of treatment, mice began the Morris
water maze task, including probe trials. On day 36, the mice performed the Y-maze
task for a single day. On day 37, mice were euthanized and brain tissue was extracted
and stored at -80°C.

Morris water maze
Spatial memory functions were assessed in the hidden version of the Morris
water maze (MWM) task. Through trial and error, mice had to spatially associate
distal extramaze cues with a submerged escape platform in order to learn of its
location (Gulinello 2009, Vorhees 2006). The apparatus consisted of a white pool with
a 24” radius and 30” height. Water was added to a depth of 14”, just above the height
of a 10cm2 Plexiglas platform. The water was mixed with a washable, non-toxic white
paint to keep it opaque. The temperature was maintained at around 25°C during
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experimentation. At the start of the third week of pomegranate administration, mice
were given a habituation trial in which they swam freely for 60 seconds. On the
following day, and for a total of 10 days, each animal was given three timed trials to
find the escape platform. For each trial, the mouse was placed in a different quadrant
from which to start its task. The position of the platform remained fixed throughout
the daily training sessions. A successful trial was defined as any attempt by which the
location of the platform was determined within a maximum of 60 seconds. Upon
completion of a successful trial, the mouse was allowed to sit for a maximum of 10
seconds on the platform before being removed. If a trial was unsuccessful, the mouse
was gently guided to the platform and allowed to sit for a maximum of 30 seconds.
Probe trails on day 1 and day 11 after the last day of the 10 acquisition sessions were
conducted to assess long-term memory retention. On these days, each mouse was
given a single trial lasting 60 seconds to show preference for the quadrant in the maze
that previously held the hidden platform. A digital video-tracking system recorded the
swim path and latency of each animal while locating the platform, as well as the time
spent in each quadrant, to allow for accurate data collection (ObjectScan; Clever Sys.,
Inc., Reston, VA, USA).

Y-maze
The Y-maze was performed on day 36 of the experiment, immediately
following the second probe trial for the MWM task. This test is based on a rodent’s
innate curiosity to explore novel areas over areas that have already been visited. The
apparatus consisted of a white maze with three paths or ‘arms’ that conjoined in the
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middle. Each arm was 12” long, 3” wide, and with 8” high walls. For this task, the
spontaneous alternation ratio was calculated for each animal to assess its spatial
working memory functions. This ratio is defined as the number of new arm entries (an
arm that is different from the previous two visited) to total arm entries minus two.
Mice were placed into a single arm and allowed to roam between the arms for five
minutes. Following each trial, the maze was cleaned with 70% ethanol. Trials were
tracked and recorded using a computerized video-tracking system (ObjectScan; Clever
Sys., Inc.), and the resulting data were analyzed.

Protein extraction and Western blotting
Cortex and hippocampal brain tissue was first homogenized using mechanical
grinding in radioimmunoprecipitation assay (RIPA) lysis buffer made up of 10mM
Tric-HCL (pH 7.4), 150mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate,
1mM ethylenediaminetetraacetic acid, and 0.1% protease inhibitor cocktail.
Homogenates were centrifuged at 10,000 x g for 20 minutes at 4°C and the
supernatant was collected. Protein concentration was determined using the BCA kit
(Pierce Biotechnology, Inc, Rockford, IL, USA). Forty micrograms of total protein
was first separated on precast 4-15% sodium dodecyl sulfate polyacrylamide gels
(Bio-Rad Laboratories, Inc, Hercules, California, USA). Protein was then transferred
onto polyvinylidiene diflouride membranes (GE Healthcare, Piscataway, NJ, USA).
Membranes were blocked for 20 minutes using Tris-Buffered saline with 0.1%
Tween-20 (TBST, pH 7.4). The membranes were then incubated overnight at 4°C with
a specific antibody diluted in TBST [1:1000 dilution of Anti-APP A4 antibody for
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APP, 1:1000 dilution of Anti-Neprilysin antibody for neprilysin, and 1:000 dilution of
PC730 Anti-IDE for insulin degrading enzyme (EMD Millipore Corporation,
Billerica, MA, USA)]. Membranes were washed three times with TBST and then
incubated for 1 hour with a 1:5000 dilution of anti-mouse or anti-rabbit IRDye 680
(Li-Cor Bioscience, Lincoln, NE, USA) at room temperature. Membranes were again
washed three times with TBST. Images were captured using the Li-Cor Odyssey
infrared imaging system (Li-Cor Bioscience). Membranes were also reprobed with an
antibody for the protein Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) at a
1:5000 dilution (Sigma-Aldrich Corp., St. Louis, MO, USA) as a control to obtain the
specific target-protein/GAPDH ratio. The intensities of the Western blot bands were
measured using the Odyssey V1.2 software (Li-Cor Bioscience).

Aβ ELISA
Enzyme-linked immunosorbent assay (ELISA) kits were used to measure
levels of soluble Aβ1-40 and Aβ1-42 (Immuno-Biological Laboratories, Gunma, Japan).
These kits are solid-phase ELISA with highly specific antibodies that are 100%
reactive with mouse Aβ1-40 with a sensitivity of 5.00pg/mL, and 70% reactive with
mouse Aβ1-42 with a sensitivity of 4.03pg/mL. Both fragments of Aβ were measured in
protein samples from the cortex and hippocampus of each animal. The protocol for the
assay was followed in accordance with a method that has already been described
(Morishima-Kawashima 2000, Wu 2008). The Aβ levels in the samples were
calculated based on the standard curve generated from each plate.
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γ-secretase (GACE) ELISA
An ELISA kit highly specific for mouse γ-secretase was used to measure it’s
concentration in cortical tissue homogenates. The kit specifically measured the
concentration by using an immunogen than binds to the presenilin enhancer 2 (PEN-2)
subunit of γ-secretase (Cusabio Life science, Wuhan, P.R. China). PEN-2 serves as an
essential cofactor of the γ-secretase enzyme (Luo 2003). The kit is a sandwich ELISA
with a minimum detection limit of 1.95pg/mL. The protocol used for the kit was
strictly consistent with that of the company’s. The γ-secretase levels in the samples
were calculated based on the standard curve generated from the plate.

Data analysis
The results for each treatment group for all behavioral and biochemical tests
were expressed as the mean ± the standard error of the mean (SEM). Significant
differences between the various treatment groups for all data were determined by oneway analysis of variance (ANOVA) with Tukey-Kramer multiple comparison a
posteriori analysis. For the MWM daily training sessions, performance within each
group was measured by a two-tailed Student’s t-test. All data were analyzed using the
GraphPad Instat 3 software (GraphPad Software, La Jolla, CA, USA) where a p-value
<0.05 was considered statistically significant.
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CHAPTER 4

FINDINGS

Pomegranate treatment does not reverse the cognitive deficits in aged hemizygous
R1.40 mice
The R1.40 model has been previously shown to possess learning and memory
deficits during late age, as determined by the MWM and Y-maze tasks (Subaiea
2013). It was hypothesized that daily treatment with pomegranate extract would
attenuate and reverse these deficits at this late age. Hemizygous R1.40 mice ranging
from 24 to 30 months were treated with 100 and 200 mg/kg/d pomegranate extract for
three weeks. In the MWM task, daily training produced a significant improvement in
escape latency between the first and last day within each group (Fig. 1A). However,
there were no significant differences between any of the groups in daily learning
acquisition. The probe trials, which test for retention of long-term memory, also
showed a lack of significance between the groups as determined by ANOVA when
compared on day 11 (Fig. 1B). The Tukey-Kramer HSD post hoc test showed that
both the 100 mg/kg/d (HSD=1.36, p>0.05) and the 200 mg/kg/d (HSD=1.16, p>0.05)
failed to reach significance.
The ANOVA results from the spontaneous alternation ratio in the Y-maze
showed a lack of significant improvement in working memory (F(2,14)=2.02,
p=0.169) (Fig. 2). The Tukey-Kramer HSD post hoc test revealed a lack of
improvement with both the 100 mg/kg/d and 200 mg/kg/d treatment groups.
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Fig. 1. Morris water maze and probe trail results. Administration of pomegranate to
hemizygous R1.40 mice fails to improve spatial memory and long-term memory. Pomegranate
extract was given for a total of 21 days via oral gavage. (A) Daily spatial acquisition trials given to
100 and 200 mg/kg/d and vehicle groups in the MWM. (B) Probe trials on day 1 and 11, following
the last day of acquisition training, to test for retention of long term memory. Significance between
the treated groups and the vehicle group was determined by one-way analysis of variance with
Tukey-Kramer post hoc test (p<0.05). Analysis was done using the GraphPad InStat 3 software.
Vehicle, n=7; 100 mg/kg/d, n=7; and 200 mg/kg/d, n=6.
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Fig. 2. Y-maze spontaneous alternation results. Performance of working memory in
hemizygous R1.40 mice treated with pomegranate extract as reflected by the spontaneous
alternation ratio in the Y-maze. There were no significant differences in performance between the
groups as assessed by one-way analysis of variance with Tukey-Kramer post hoc test (p<0.05).

Pomegranate treatment does not lower cortical and hippocampal APP protein levels
Levels of cortical and hippocampal APP were analyzed by Western blot for all
the groups and normalized against the housekeeping protein GAPDH (Fig. 3). Levels
of APP are expressed as the APP/GAPDH ratio. It was revealed by ANOVA that there
were no significant differences in protein levels for both the cortex (F (2,6)=0.252,
p=0.785) and hippocampus (F (2,15)=3.13, p=0.073). The Tukey-Kramer post hoc test
confirmed that both the 100 mg/kg/d and 200 mg/kg/d treatments were not
significantly different from the vehicle for both brain regions.

Pomegranate treatment does not increase cortical IDE protein levels
A function of insulin degrading enzyme (IDE) is the cerebral degradation of
Aβ peptides (Kurochkin 1994). Western blotting was used to measure its levels in the
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cortex and determine if they were affected by pomegranate treatment (Fig. 4). The
band intensities were normalized against GAPDH to obtain the ratio. It was shown by
ANOVA that there were no significant differences in IDE between the groups
(F(2,14)=1.36, p=0.290).
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Fig. 3. Amyloid precursor protein levels. Levels of amyloid precursor protein (APP) remained
unchanged in hemizygous R1.40 mice after treatment with pomegranate. (A) Western blot analysis
of cortical APP levels, reflected as the ratio of APP to the housekeeping protein GAPDH. (B)
Western blot analysis of hippocampal APP levels. Significance was determined by one-way
analysis of variance with Tukey-Kramer post hoc test (p<0.05). Results were obtained using the
GraphPad InStat 3 software.
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Fig. 4. Insulin degrading enzyme levels. Levels of IDE remained the same in hemizygous R1.40
mice after treatment with pomegranate. IDE was checked in the cortex and normalized against
GAPDH. Significance was determined by one-way analysis of variance with Tukey-Kramer post
hoc test (p<0.05). Results were obtained using the GraphPad InStat 3 software.

Pomegranate treatment increases levels of Aβ1-40, decreases levels of Aβ1-42, and
decreases the Aβ42/Aβ40 ratio, in both the cortex and hippocampus
ELISA was used to measure concentrations of soluble Aβ1-40 and Aβ1-42 in both
the cortex and hippocampus. Additionally, the Aβ42/Aβ40 ratio was obtained for each
sample by dividing the levels of each peptide, which was obtained from ELISA.
Studies have suggested that the ratio serves as a better predictor of AD plaque load in
the brain (Yin 2007). ANOVA revealed that for the cortex, there was a significant
increase in Aβ1-40 (F(2,15)=4.11, p=0.038) (Fig. 5A). The Tukey-Kramer HSD post
hoc test indicated that levels for the 200 mg/kg/d group were significantly higher
(HSD=3.87, p<0.05), whereas the 100 mg/kg/d group failed to reach significance
(HSD=0.91, p>0.05). For Aβ1-42, ANOVA showed a significant decrease in their
levels in the cortex (F(2,16)=4.88, p=0.022) (Fig. 5B). The HSD post hoc test showed
that levels for both the 100 mg/kg/d (HSD=3.89, p<0.05) and the 200 mg/kg/d
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(HSD=3.66, p<0.05) treatment groups were lowered significantly. The Aβ42/Aβ40
ratio results were also analyzed and it was shown by ANOVA that it had decreased
significantly (F(2,14)=8.90, p=0.003), but the HSD post hoc test showed that it had
decreased significantly for the 200 mg/kg/d treatment group (HSD=5.94, p<0.01) and
not the 100 mg/kg/d (HSD=3.27, p>0.05) (Fig. 5C).
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Fig. 5. Changes in cortical Aβ1-40 and Aβ1-42. Cortex concentrations of soluble Aβ changed in
hemizygous R1.40 mice after treatment with pomegranate. (A) Soluble Aβ1-40. (B) Soluble Aβ1-42.
(C) Aβ42/Aβ40 ratio, obtained by dividing the ELISA result for each peptide. *Values are
significantly different from vehicle, as determined by one-way analysis of variance with TukeyKramer post hoc test (p<0.05). Analysis of results was done using the GraphPad InStat 3 software.

For the hippocampus, ANOVA revealed that there were similar alterations in
the Aβ peptides, and thus, also the ratio. Levels of Aβ1-40 increased significantly
(F(2,17)=6.62, p=0.007), with the Tukey-Kramer HSD post hoc test showing a
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significant increase for both the 100 mg/kg/d group (HSD=3.98, p<0.05) and the 200
mg/kg/d group (HSD=4.77, p<0.01), when comparing all columns (Fig. 6A). The
levels of Aβ1-42 changed even more significantly (F(2,17)=62.4, p<0.0001). The HSD
post hoc test showed that the 200 mg/kg/d group was significantly lower than both the
100 mg/kg/d group (HSD=11.94, p<0.001) and the vehicle (HSD=15.16, p<0.001).
The 100 mg/kg/d group (HSD=3.36, p>0.05) did not reach significance (Fig. 6B). As
expected, the Aβ42/Aβ40 ratio was lowered significantly (F(2,17)=38.28, p<0.0001)
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Fig. 6. Changes in hippocampal Aβ1-40 and Aβ1-42. Hippocampal concentrations of soluble Aβ
changed in hemizygous R1.40 mice after treatment with pomegranate. (A) Soluble Aβ1-40. (B)
Soluble Aβ1-42. (C) Aβ42/Aβ40 ratio, obtained by dividing the ELISA result for each peptide.
*Values are significantly different from the vehicle group. **Values are significantly different from
the 100 mg/kg/d and vehicle group. Significance was determined by one-way analysis of variance
with Tukey-Kramer post hoc test (p<0.05). Analysis of results was done using the GraphPad InStat
3 software.
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(Fig. 6C). The HSD post hoc test reported a significant decrease in the 200 mg/kg/d
group when compared to both the 100 mg/kg/d group (HSD=7.60, p<0.001) and the
vehicle (HSD=12.32, p<0.001). The 100 mg/kg/d group (HSD=4.92, p<0.01) also
reached significance.

Pomegranate increases levels of γ-secretase in the cortex
An ELISA kit was used to determine whether the levels of γ-secretase changed
with pomegranate treatment. Any changes would help explain the shift in the
preference for the Aβ1-40 peptide, since γ-secretase provides the final cleavage of APP

γ-Secretase Levels pg/mg

before generating Aβ. It’s important to note that the results of this method would
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Fig. 7. Changes in γ-Secretase levels. Levels of γ-Secretase in the cortex changed after treatment
with pomegranate. *Values are significantly different from the vehicle group. Significance was
determined by one-way analysis of variance with Tukey-Kramer post hoc test (p<0.05). Analysis
of results was done using the GraphPad InStat 3 software.

reveal very little about the actual activity of this enzyme. After the results were
obtained, ANOVA showed that there was significant increase in its levels
(F(2,17)=4.71, p=0.024) (Fig. 7). The Tukey-Kramer HSD post hoc test revealed that
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the 100 mg/kg/d group reached significance (HSD=3.98, p<0.05), but not the 200
mg/kg/d group (HSD=3.42, p>0.05) when comparing all columns.
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CHAPTER 5

DISCUSSION AND CONCLUSION
In recent years, there has been an increase in evidence supporting the relation
between the intake of certain natural products and the decreased risk of developing
Alzheimer’s disease (Essa 2012). Fruits in particular have received considerable
attention because of their many disease-fighting compounds and antioxidant properties
(Dai 2006, Hughes 2010). However, very little research has addressed these effects
during the late stages of AD. In this study, a pomegranate peel extract, which has
considerable levels of antioxidant polyphenols, was administered to hemizygous
R1.40 mice aged 24-30 months for three weeks to determine its effects on both the
cognitive and pathological features of the disease. In addition, the mechanism of
action of pomegranate in the aging AD brain was analyzed. It was hypothesized that a
short-term treatment of pomegranate peel extract would help to reverse cognitive
decline and plaque deposition in the AD mouse model.
According to the results obtained from the Morris water maze daily trials, all
of the groups showed a significant decrease in escape latency throughout the course of
the daily acquisition trails. This performance is expected with relative learning
behaviors. However, the treated groups did not show significant improvement in
spatial learning compared to the control. In addition, there was no significant
improvement in long-term memory retention, as shown by the delayed probe trials on
day 1 and 11 following the MWM. There was also a lack of improvement in working
memory, as tested by the Y-maze. It has been suggested that recent spatial memory is
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hippocampal dependent, while remote spatial memory is dependent on the medial
prefrontal cortex (Frankland 2005, Teixeira 2006).
Working memory is also cortical and hippocampal dependent (Lalonde 2002).
In the R1.40 mouse model, both the frontal cortex and hippocampus have diffuse Aβ
deposits at 24-26 months of age (Lamb 1999). Deposition of Aβ peptides, especially
Aβ1-42, leads to increased oxidative stress and neuroinflammation, resulting in the
neuronal loss and AD pathogenesis (Butterfield 2002). It was hypothesized that the
antioxidant polyphenols from pomegranate could inhibit this cascade of events at this
late stage in the treated groups, perhaps at multiple points in the pathway, and result in
a gain of neuronal function. It can be concluded that there was already extensive
neuronal loss in this model at the start of the study and treatment with pomegranate
does not reverse these losses. These findings, however, support the reliability of this
transgenic animal as a model for researching AD. Improvements in spatial learning
and memory have already been seen in a previous study using this model. Treatment
with a pharmacological drug at an early age produced significant cognitive
improvements compared to vehicle controls (Subaiea 2013).
The effects of pomegranate extract on the biochemical aspects of AD were
determined by focusing on changes in important AD biomarkers in the brain. The
levels of the amyloid precursor protein (APP), which is the precursor to Aβ peptides,
did not change between the groups. This was found with both brain regions. These
results are consistent with previous findings with pomegranate (Hartman 2006). Since
APP remained unaffected, its proteolytic processing into Aβ peptides was the next
target for consideration.
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An interesting effect was seen with the soluble levels of Aβ1-40 and Aβ1-42. It
appears that treatment significantly inhibited the production of the longer Aβ1-42
subtype in favor of the shorter Aβ1-40 one. These trends were consistent in both the
cortex and hippocampus. This shift in preference resulted in significant decreases in
the Aβ42/Aβ40 ratios, especially with the 200 mg/kg/d treatment. It has been
previously reported that although the Aβ1-40 fragment appears at levels ten times more
than its longer counterpart in AD, it exhibits neuroprotective properties by inhibiting
the aggregation and deposition of Aβ1-42 in the brain (Kim 2007, Wang 2006, Yan
2007). It has also been found that a decreased production of the Aβ1-40 subtype due to
altered function in γ-secretase leads to exacerbated plaque pathology in mice (Deng
2006). Studies also suggest that lowering the Aβ42/Aβ40 ratio has more implications
for AD therapy than simply lowering the absolute amount of Aβ (Kuperstein 2010).
The Aβ results from this study point to a specific mechanism of action for
pomegranate in combating AD pathogenesis. In order to explain the changes in these
Aβ peptides, a number of hypotheses had to be proposed. Alterations in Aβ could be
due to changes in its clearance rates. It also could have been due to changes in its
generation. To test the first, levels of insulin degrading enzyme (IDE) were measured.
IDE regulates the levels of both insulin and Aβ in the body through their
degradation (Kurochkin 1994). In this study, it was found that the levels of IDE
protein remained unaffected by pomegranate extract treatment. It can be strongly
asserted that pomegranate does not alter the Aβ profile by inducing its clearance from
the brain. These results pointed to a more specific target for pomegranate; a target that
is more determinative about the quality of Aβ that is generated, as shown by the
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changes in the Aβ42/Aβ40 ratios, instead of quantity of Aβ. This target would most
likely be γ-secretase.
BACE1 is the initial enzyme that cleaves APP extracellularly and creates two
fragments; the soluble extracellular fragment termed sAPPβ and a cell membranebound fragment known as C99. The latter fragment serves as the substrate for
cleavage by γ-secretase and thus the generation of Aβ. γ-secretase is responsible for
the heterogenous cleavage of this fragment into a variety of Aβ subtypes, and thus
represents the target for consideration in this study. ELISA was used to measure γsecretase and determine its changes in the brain after treatment with pomegranate
extract. This test was limited in that it told only about the changes in the concentration
of γ-secretase, but not its catalytic activity. However, changes in its concentration can
perhaps be directly associated with its levels of catalytic activity in the brain. The
results showed that the relative amount of γ-secretase increased with treatment, but
significantly only with the 100 mg/kg/d group. The 200 mg/kg/d group failed to reach
significance by a narrow margin. This disquieting lack of significance can perhaps be
explained by noting that gamma-secretase was measured only in the cortex, and not in
the hippocampus. When analyzing the changes in the Aβ subtypes from the cortex, it
appears that the 200 mg/kg/d group is showing levels that are within range of the
levels of the 100 mg/kg/d group. However, the treatment’s specific effects are more
apparent when analyzing the hippocampus region. It appears that the Aβ trends were
statistically stronger in the hippocampus tissue than in the cortex. The ANOVA tests
revealed that the p-values were considerably smaller for the both Aβ subtypes and
ratio in the hippocampus, in comparison to the cortex. Perhaps the treatment has more
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favorable outcomes in one brain region compared to another. Conducting the γsecretase ELISA on the hippocampus would help confirm these results.
There are two general explanations as to why the γ-secretase levels are
increasing with treatment. First, the mRNA expression of its subunits could be
increasing, thus changing its amount of translation and assembly. Secondly, it's
possible that with treatment, its eventual degradation from the cell is being
downregulated. Regardless of these explanations, the question is how an increase in its
levels relates to a change in the Aβ42/Aβ40 ratio. It can be hypothesized that the
catalytic activity of γ-secretase is indeed being modulated, perhaps to favor the
production of the shorter Aβ peptide.
Even though there have been many studies elucidating the structure and
function of γ-secretase, little is known about the mechanisms that regulate its cleavage
specificity. This specificity is crucial for the pathogenesis of AD. It has already been
suggested that mutations in the transmembrane portion of C99 can alter the interaction
between C99 and γ-secretase, thus changing its cleavage specificity (Lichtenthaler
1999). More recently, it has been proposed that altering single amino acid residues at
the cytosolic face of the C99 substrate alters the specificity of γ-secretase binding, thus
modifying the levels of each Aβ species that is produced (Ousson 2013). Nevertheless,
to further investigate the implications of changing γ-secretase levels, it is important to
look at its likely structure and function within this model.
The structure of γ-secretase has been found to be made up of four subunits,
with PS-1 or presenilin-2 (PS-2) present at its catalytic core (Ogura 2006). Expression
of all four proteins is necessary for its activity (Edbauer 2003). It has been widely
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established that mutations in PS-1 cause significant elevations in extracellular Aβ1-42,
promoting its deposition into plaques (Scheuner 1996). However, since the model used
for this study does not have the PS-1 mutation, the focus shifts to whether or not the
wild-type PS-1 plays a role in γ-secretase activity and AD pathogenesis. Interestingly,
it has been found that the presence of the wild-type PS-1 form in a PS-1 mutant mouse
leads to lessened amyloid plaque pathology, compared to its absence. This establishes
a protective role for wild-type PS-1 (Wang 2006). However, whether or not it exhibits
any protection in the presence of the APPsw mutation used in this study remains to be
elucidated. It would be interesting to measure the levels of wild-type PS-1 between the
groups and determine any changes in its expression and activity. This also applies to
the other subunits of the γ-secretase complex.
Another interesting target for consideration is BACE1. It has been previously
found that the pomegranate peel contains compounds that work to inhibit BACE1
activity (Kwak 2005). Any inhibition of BACE1 by pomegranate would decrease APP
processing and formation of Aβ peptides. However, BACE1 is unlikely to be the target
for pomegranate activity in this study because its inhibition would create less of the
C99 fragment, and thus decrease both the Aβ1-40 and Aβ1-42 species that are generated
from its cleavage by γ-secretase. The results of this study indicate a different effect.
Considering the changes in the Aβ42/Aβ40 ratio and the γ-secretase levels, it
appears as though pomegranate is acting as a modulator of γ-secretase. Modulators of
this enzyme have already been extensively studied as therapeutic agents for AD.
Shifting the formation of Aβ into the shorter, less toxic peptides has been a recent
target for AD therapy (Peretto 2008). A large phase-3 clinical study on a drug called
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tarenflurbil found that it shifts γ-secretase activity to form less of the Aβ1-42 subtype in
favor of shorter forms such as Aβ1-38. However, this drug failed to improve cognition in
patients with mild-AD, possibly due to low brain penetrability (Marder 2010).
γ-secretase modulators have been more promising for AD therapy compared to
inhibitors of this enzyme. It is know that in addition to cleaving the C99 fragment of
APP, γ-secretase also cleaves a transmembrane protein called Notch. Cleavage of
Notch into an intracellular domain induces a signaling pathway that mediates cell-cell
communication and is important for cell-fate decisions (Baron 2003). Inhibition of γsecretase can prevent the necessary processing of Notch and thus lead to a variety of
side effects and developmental issues (Geling 2002). In addition to being a modulator
of γ-secretase instead of an inhibitor, pomegranate possesses no toxicity associated
with its consumption and thus represents an ideal fruit for further investigation.
Some limitations of this study to note are as follows. First, the highest dose
used for treatment was dependent on the solubility of the powdered extract in saline,
which was the control treatment. Use of additional measures, such as heat, to dissolve
more extract may have compromised its integrity. Secondly, this study employed aged
transgenic mice of AD. The successful administration of the treatment and completion
of the behavioral tasks was contingent on the animals’ ability to withstand these stressinducing measures. The animals’ health was continuously monitored to ensure that
they were capable of continuing the trials. Possible reductions in numbers were taken
into consideration when determining the initial sample size of each group.
In conclusion, this study looked at the efficacy of a pomegranate peel extract in
rescuing the cognitive deficits of aged R1.40 transgenic mice and modifying AD
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plaque pathology. Even though a lack of effect was seen with learning and memory, a
specific mechanism of action can be proposed for pomegranate in the AD brain. This
mechanism involves the modulation of the enzyme γ-secretase. It is not exactly known
which class of compounds from pomegranate may be promoting this modulatory
effect. It is known, however, that pomegranate has a number of polyphenols with
strong antioxidant activities in the brain. Whether it is acting through a separate
mechanism by selectively targeting toxic Aβ1-42 species remains to be known. In
addition, further investigation on the workings and activity of γ-secretase on the
APP/C99 fragment is needed to help determine on a molecular basis how modulatory
compounds must be exerting their effects. In addition, a thorough evaluation of how
antioxidants enter the brain to reduce Aβ plaque pathology and interact with and
protect neurons is necessary. A thorough understanding of how certain therapies
alleviate the symptoms of AD is contingent on the understanding of the basic
molecular implications of AD in the aging brain.
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